comparemela.com

Latest Breaking News On - Nmcrpc - Page 1 : comparemela.com

Dr Dreicer on the Different Approaches to mCRPC Management

Robert Dreicer, MD, discusses different approaches in prostate cancer management according to the type of oncologist.

Robert dreicerDivision of hematology oncologyUniversity of virginia cancer centerVirginia cancer centerProstate cancer management

Dr Hussain on Key Ongoing Clinical Trials in Metastatic Castrate-Resistant Prostate Cancer

Maha Hussain, MD, FACP, FASCO, discusses clinical trials evaluating therapeutics for patients with metastatic castrate-resistant prostate cancer.

Maha hussainNorthwestern university feinberg school of medicineDepartment of medicineRoberth lurie comprehensive cancer centerGu oncology programDivision of hematologyComprehensive cancer centerNorthwestern university feinberg schoolCancers symposiumProstate cancerContact 2 trial nct04446117Rcaaway trial nct03012321

APEX-01 Looks to Add First PSMA-Directed ADC to Treatment Paradigm in mCRPC

John Shen, MD, discusses the phase 1/2 APEX-01 trial of ARX517 in metastatic castration-resistant prostate cancer.

Los angelesUnited statesJohn shenUniversity of californiaWorldj mens healthLos angeles healthDuring the european society for medical oncologyEuropean societyMedical oncologyPreliminary efficacyWorldj mensProstate cancerPhase 1 2 apex 01 trial nct04662580Antibody drug conjugate

Post-Hoc Analysis of ARASENS Reinforces Use of Darolutamide/ADT/Docetaxel Combo as SOC in mHSPC

A post-hoc analysis of censored patients with mHSPC showed benefit with darolutamide, ADT, and docetaxel, supporting primary data from the ARASENS trial.

Neald shore

Olaparib Plus Abiraterone/Prednisone Displays Efficacy in mCRPC

Frontline treatment with olaparib plus abiraterone/prednisone led to a PFS benefit vs olaparib or abiraterone/prednisone alone in BRCA1/2– or ATM–altered mCRPC.

Maha mussainNorthwestern universityFeinberg schoolMetastatic castration resistant prostate cancer2024 genitourinary cancers symposium

vimarsana © 2020. All Rights Reserved.